An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 730 participants.
Also called NCT03354273
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 730 participants
- Sponsor
- Registry
-
NCT03354273 -
2017-005011-14
-
- Other papers using this trial's data
- Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease
- Improved assessment of coronary artery disease in obese patients with flurpiridaz-18F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Finland, France, Germany, Netherlands, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT03354273. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-06-05 (actual); primary completion 2022-05-05 (actual). Results posted on 2023-07-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
- Intervention (Drug)
- PET MPI
- Intervention (Drug)
- SPECT MPI
- Intervention (Drug)
- Pharmacological stress agents
- Lead sponsor
- GE Healthcare
- Collaborator
- Pharmaceutical Product Development, (PPD) LLC
Record details
- Record id
cardio:ct-nct03354273- Content hash
da0d9a0cd3549d504a4f8b12f03f4241d695fe84890c9d0a923f286f59fed660